Ancon Medical Seeks Funding for Revolutionary Lung Cancer Early Detection Screening Device

December 8, 2014 3:50 PM

3 0

A new, non-invasive lung screening technology developed by American medical device maker Ancon Medical Inc. offers the capability to detect presence of early-stage lung cancer at a fraction of the cost of conventional methods. Ancon, based in Minnesota’s “LifeScience Alley” at Bloomington, seeks funding necessary to finalize and ramp up production of its Nanoparticle Biomarker Tagging (NBT) device, heralded as a better and cheaper alternative than CT scans that works by detecting a variety of infectious diseases and viruses by analyzing gaseous elements in a patient’s breath.

Early detection is important with any cancer, but especially crucial in lung cancer, where detection of which can be a challenge for medical professionals since standard x-rays are ineffective at finding lung cancer tumors in their earliest stages when the best opportunity for cure of the disease ex...

Read more

To category page

Loading...